The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis
Open accessAbstract
BACKGROUND & AIMS: There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis. METHODS: We performed a double-blind trial of 291 patients with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy. The study was performed at 18 clinical sites in France from April 2010 through November 2014. Patients were randomly assigned to groups given 400 mg norfloxacin (n = 144) or placebo (n = 147) once daily for 6 months. Patients were evaluated monthly for the first 6 months and at 9 months and 12 months thereafter. The primary outcome was 6-month mortality, estimated by the Kaplan-Meier method, censoring spontaneous bacterial peritonitis, liver transplantation, or loss during follow-up. RESULTS: The Kaplan-Meier estimate for 6-month mortality was 14.8% for patients receiving norfloxacin and 19.7% for patients receiving placebo (P = .21). In competing risk analysis that took liver transplantation into account, the cumulative incidence of death at 6 months was significantly lower in the norfloxacin group than in the placebo group (subdistribution hazard ratio, 0.59; 95% confidence interval, 0.35-0.99). The subdistribution hazard ratio for death at 6 months with norfloxacin vs placebo was 0.35 (95% confidence interval, 0.13-0.93) in patients with ascites fluid protein concentrations <15 g/L and 1.39 (95% confidence interval, 0.42-4.57) in patients with ascites fluid protein concentrations ≥15 g/L. Norfloxacin significantly decreased the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria. CONCLUSIONS: In a randomized controlled trial of patients with advanced cirrhosis without recent fluoroquinolone therapy, norfloxacin did not reduce 6-month mortality, estimated by the Kaplan-Meier method. Norfloxacin, however, appears to increase survival of patients with low ascites fluid protein concentrations. ClinicalTrials.gov ID: NCT01037959.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Fernández, J., Navasa, M., Gómez, J., Colmenero, J., Vila, J., Arroyo, V., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.30082 · Cited by 954
Fernández, J., Navasa, M., Planas, R., Montoliu, S., Monfort, D., Soriano, G., Vila, C., Pardo, A., Quintero, E., Vargas, V., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.065 · Cited by 709
Ginés, P., Rimola, A., Planas, R., Vargas, V., Marco, F., Almela, M., Forne, M., Miranda, M. L., Llach, J., Salmerón, J. M., et al. (1990) · Hepatology · doi:10.1002/hep.1840120416 · Cited by 627
Tandon, P., DeLisle, A., Topal, J. E., & Garcia–Tsao, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.017 · Cited by 158
Cited by
Biggins, S. W., Angeli, P., Garcia‐Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021) · Hepatology · doi:10.1002/hep.31884 · Cited by 846
Guidelines on the management of ascites in cirrhosis
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321790 · Cited by 680
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide
Piano, S., Singh, V., Caraceni, P., Maiwall, R., Alessandria, C., Fernandez, J., Soares, E. C., Kim, D. J., Kim, S. E., Marino, M., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.005 · Cited by 516
Self-citationCirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.009 · Cited by 41
“For this reason, survival has been the primary endpoint in some previous clinical trials in patients with decompensated cirrhosis.(7,9,11) In addition, overall survival should always be assessed in these trials, and patients should be followed up to the end of the trial regardless of protocol adherence.”
Metadata
- Authors
- Moreau, R., Elkrief, L., Bureau, C., Perarnau, J.-M., Thévenot, T., Saliba, F., Louvet, A., Nahon, P., Lannes, A., Anty, R., Hillaire, S., Pasquet, B., Ozenne, V., Rudler, M., Ollivier-Hourmand, I., Robic, M. A., d'Alteroche, L., Di Martino, V., Ripault, M.-P., Pauwels, A., Grangé, J.-D., Carbonell, N., Bronowicki, J.-P., Payancé, A., Rautou, P.-E., Valla, D., Gault, N., & Lebrec, D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 155
- Issue
- 6
- Pages
- 1816-1827.e9
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2888547358
- Cited by
- 170
- References
- 6
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. https://app.cochat.ai/papers/10.1053/j.gastro.2018.08.026
- The paper
- Moreau, R., Elkrief, L., Bureau, C., Perarnau, J.-M., Thévenot, T., Saliba, F., Louvet, A., Nahon, P., Lannes, A., Anty, R., Hillaire, S., Pasquet, B., Ozenne, V., Rudler, M., Ollivier-Hourmand, I., Robic, M. A., d'Alteroche, L., Di Martino, V., Ripault, M.-P., . . . Lebrec, D. (2018). Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology. https://doi.org/10.1053/j.gastro.2018.08.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.